AnaptysBio is advancing a arthritis therapy similar to Eli Lilly and Co's PD-1 agonist antibody Peresolimab.
According to the Securities Times APP, on Wednesday, AnaptysBio (ANAB.US) stock price fell, dropping more than 20% to $24.455 as of the time of publication. AnaptysBio is advancing an arthritis therapy similar to Eli Lilly and Co (LLY.US)'s PD-1 agonist antibody Peresolimab. AnaptysBio's stock price plummeted after Eli Lilly announced the decision to terminate the research on this candidate drug.
In July of this year, H.C. Wainwright initiated coverage on AnaptysBio, with a 'buy' rating and a target price of $55. The firm believes that its PD-1 agonist rosnilimab may be more effective than peresolimab. Preliminary data from rosnilimab's trials is expected to be released in the first quarter of 2025.
